Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2025-12-25 @ 8:23 PM
NCT ID:
NCT03433469
Group ID:
EG000
Title:
Treatment (Osimertinib)
Description:
Participants receive 80mg osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans, participants may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Participants then undergo non-investigational surgical resection of their cancer. No treatment with the study drug will be given after surgery.
Deaths Number Affected:
4
Deaths Number At Risk:
None
Serious Number Affected:
3
Serious Number At Risk:
27
Other Number Affected:
27
Other Number At Risk:
27
Study:
NCT03433469
Results Section:
NCT03433469
Adverse Events Module:
NCT03433469